Less Known but Clinically Relevant Comorbidities of Atrial Fibrillation: A Narrative Review.

BACKGROUND: The important risk factors for atrial fibrillation (AF) in the general population are not always equally important in specific and relatively prevalent diseases. OBJECTIVE: The main goal of this narrative review is to focus attention on the presence and the relationship of AF with several important diseases, such as cancer or sepsis, in order to: 1) stimulate further research in the field, and 2) draw attention to this relationship and search for AF in clinical practice. METHODS: We searched PubMed, SCOPUS, Elsevier, Wiley, Springer, Oxford Journals, Cambridge, SAGE, and Google Scholar for less-known comorbidities of AF. The search was limited to publications in English. No time limits were applied. RESULTS: AF is widely represented in cardiovascular and other important diseases, even in those in which AF is rarely mentioned. In some specific clinical subsets of AF patients (e.g., patients with sepsis or cancer), the general risk factors for AF may not be so important. Patients with new-onset AF have a several-fold increase in relative risk of cancer, deep vein thrombosis, and pulmonary thromboembolism (PTE) during the follow-up. CONCLUSION: AF presence, prognosis, and optimal therapeutic approach are insufficiently recognised in several prevalent diseases, including life-threatening ones. There is a need for a better search for AF in PTE, pulmonary oedema, aortic dissection, sepsis, cancer and several gastrointestinal diseases. Improved AF detection would influence treatment and improve outcomes.

Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome.

To date, many questions about the extent and cause of pharmacokinetic (PK) variability of even the most widely studied and prescribed ß1-adrenergic receptor blockers, such as metoprolol and bisoprolol, remain unanswered. Given that there are still no published population pharmacokinetic (PopPK) analyses of bisoprolol in routinely treated patients with acute coronary syndrome (ACS), the aim of this study was to determine its PK variability in 71 Serbian patients with ACS. PopPK analysis was conducted using a nonlinear mixed-effects model (NONMEM), version 7.3.0 (Icon Development Solutions). In each patient, the same formulation of bisoprolol was administered once or twice daily at a total daily dose of 0.625-7.5 mg. We separately assessed the effects of 31 covariates on the PKs of bisoprolol, and our results indicated that only 2 covariates could have possible influence on the variability of the clearance of bisoprolol: the mean daily dose of the drug and smoking habits of patients. These findings suggest that possible autoinduction of drug metabolism by higher total daily doses and induction of cytochrome P450 isoform 3A4 (CYP3A4) by cigarette smoke in liver could be the potential causes of increased total clearance of bisoprolol in patients with ACS.

Heart failure caused by cardiac rhabdomyosarcoma.

Rhabdomyosarcoma accounts for 20% of primary malignant cardiac tumours. We describe a woman with cardiac rhabdomyosarcoma. She had loss of appetite, loss of weight, and symptoms of heart failure. A mobile tumour in the left atrium, entering the left ventricle during diastole, was detected by transthoracic echocardiography. The tumour was removed surgically in total; histological diagnosis was rhabdomyosarcoma; however, the patient died after 6 months. In conclusion, primary malignant cardiac tumours can simulate heart failure or systemic disorders. Cardiac rhabdomyosarcomas have a poor prognosis with average survival of 6 months after diagnosis.

Association of stress hyperglycemia and atrial fibrillation in myocardial infarction.

BACKGROUND: Stress hyperglycemia has an untoward effect on prognosis in acute myocardial infarction (AMI). Evidence on the interrelationship between stress hyperglycemia and atrial fibrillation (AF) in AMI is sparse. We hypothesized that stress hyperglycemia and AF, both being markers of worse in-hospital prognosis, may be interrelated and we therefore analyzed the relationship between stress hyperglycemia and AF in AMI. PATIENTS AND METHODS: The study was a retrospective analysis of 543 patients with AMI. The average age was 63.8 +/- 10.6 years and 54.9% were male. RESULTS: AF was more prevalent in 200 AMI patients with admission glucose >or= 8.0 mmol/l (15.00%) than in 343 patients with admission glucose < 8 mmol/l (7.87%), Pearson's chi-squared P = 0.010, OR 2.07 (95% CI 1.180-3.637). In AMI patients with neither stress hyperglycemia nor AF, in-hospital mortality was 1.67%; in patients with stress hyperglycemia without AF, the mortality was 3.85%. In patients with AF without stress hyperglycemia, mortality was high at 13.04%, and in patients with both stress hyperglycemia and AF it was extremely high at 24.14%. Hyperglycemia (r = 0.1680, P = 0.0472) but not AF correlated with the size of the AMI. Compared with an AF prevalence of 8.28% in the normoglycemic group, AF was found more often (14.65%) in a group with diabetes mellitus (DM), Pearson's chi-squared P = 0.02, OR = 2.04 (95% CI 1.06-3.93). There was no significant difference in the occurrence of AF between patients with previously diagnosed DM and those with new-onset DM (Fisher's exact test P = 0.34). CONCLUSIONS: Stress hyperglycemia is associated with increased prevalence of AF in AMI. Patients with both stress hyperglycemia at admission (>or= 8.0 mmol/l) and AF had almost 14.5 times higher in-hospital mortality than patients who had neither stress hyperglycemia nor AF. Stress hyperglycemia was an independent predictor of the in-hospital mortality in multivariate regression analysis, but AF was not.

[Cardiac rhabdomyosarcoma].

BACKGROUND: Primary malignant cardiac tumors are rare entities and rhabdomyosarcoma accounts 20% of these lesions. CASE REPORT: We presented a female patient with loss of appetite and loss of weight. She also had symptoms of heart failure and bilateral pleural effusions. A mobile tumor in the left heart with the entrance from the left atrium to left ventricle during diastole was seen by transthoracic echocardiography. The tumor was extirpated in total, histologic diagnosis was rhabdomyosarcoma, and the patient died after 6 months. CONCLUSION: Primary malignant cardiac tumors can simulate heart failure or systemic disorders. Cardiac rhabdomyosarcomas have a poor prognosis with the average survival of 6 months after the occurrence of symptoms and making a diagnosis. In cardiac insufficiency, differential diagnostics should be used to consider cardiac tumors that could be with certainty confirmed or excluded by echocardiography.